News & Updates

New drug applications approved by US FDA as of 16-31 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Fall episodes in individuals with atrial fibrillation (AF) may signal poor outcomes, including intracranial haemorrhage and mortality, according to a study.

For individuals with increased projected risk of probable dementia or amnestic mild cognitive impairment (MCI) who are prescribed antihypertensive treatment, intensive systolic blood pressure (SBP) lowering confers greater cognitive benefits than standard treatment, according to a secondary analysis of the SPRINT trial.

Treatment with clevidipine in patients undergoing cardiac surgery leads to better perioperative blood pressure (BP) control relative to nicardipine, with a slight rise in cost and no significant difference in safety outcomes, a study has found.

Adding glucagon-like peptide-1 receptor agonists (GLP1RA) onto metformin, sulfonylurea, or insulin treatment alone or in combination appears to reduce the incidence of major adverse cardiac events (MACE) and heart failure (HF) hospitalization relative to treatment with dipeptidyl peptidase-4 inhibitors (DPP4i), suggests a study.